Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | Revisão |
| 語言: | 英语 |
| 出版: |
2014
|
| 在線閱讀: | https://doi.org/10.1517/14728222.2014.960843 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|